Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Tildrakizumab (ILUMYA) Use on Epigenetic Age Acceleration and Psoriasis

NCT05110313 is registered in ClinicalTrials.gov with Carlos Wambier as lead sponsor.

NCT NCT05110313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05110313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Tildrakizumab (ILUMYA) Use on Epigenetic Age Acceleration and Psoriasis
Lead sponsor
Carlos Wambier
Phase
Phase 4
Overall status
Completed
Start date
April 8, 2022
Completion date
May 27, 2024
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aging, epigenetic disorder, inflammation; skin, psoriasis